Blog
RSS FeedPosted by Michael Wonder on 27 Sep 2022
COVID-19 vaccine procurement review says rapid access to vaccines and treatments key to on-going protection of Australians
27 September 2022 - Medicines Australia welcomes the independent review of Australia’s COVID-19 vaccine and treatment procurements by Professor Jane ...
Posted by Michael Wonder on 27 Sep 2022
Halton review into vaccine and treatment procurement
27 September 2022 - Professor Jane Halton AO has handed to Government her independent review of Australia’s COVID-19 vaccine and treatment ...
Posted by Michael Wonder on 26 Sep 2022
National Medicines Policy draft strides ahead but still room for improvement
26 September 2022 - Stakeholders have until tomorrow night to submit their feedback on the refreshed National Medicines Policy that ...
Posted by Michael Wonder on 21 Sep 2022
The on- and off-ramps of oncology accelerated approval
21 September 2022 - To address ongoing concerns about the implementation of the FDA’s accelerated approval pathway in oncology, a ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC promises equity boost in first official response to independent review
6 September 2022 - PHARMAC will supercharge its commitment to Māori and diverse communities, which could see different medicines funded, ...
Posted by Michael Wonder on 05 Sep 2022
PHARMAC releases its interim response following PHARMAC review
5 September 2022 - As part of its ongoing commitment to transparency, Te Pātaka Whaioranga – PHARMAC has today shared their ...
Posted by Michael Wonder on 05 Sep 2022
Review of Efficient Funding of Chemotherapy Program - interim report
5 September 2022 - The Efficient Funding of Chemotherapy review seeks to investigate current processes involved in the production, distribution ...
Posted by Michael Wonder on 22 Aug 2022
National Medicines Policy review – registrations for targeted stakeholder consultation sessions and open public forum
22 August 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on the revised ...
Posted by Michael Wonder on 18 Aug 2022
Restart of National Medicines Policy Review is welcome, but assurances needed over further consultation and feedback processes
18 August 2022 - Medicines Australia welcomes the restart of the National Medicines Policy Review, which was put on hold ...
Posted by Michael Wonder on 17 Aug 2022
Accelerated approval of cancer drugs: no economic reward for drug makers that conduct confirmatory trials
17 August 2022 - The FDA uses expedited approval of drugs to speed the development and assessment of drugs that address ...
Posted by Michael Wonder on 17 Aug 2022
COVID vaccine rollout too slow, poorly planned, audit finds
17 August 2022 - An audit of Australia’s coronavirus vaccination rollout has criticised the slow speed at which early doses ...
Posted by Michael Wonder on 17 Aug 2022
Restart of the National Medicines Policy review – further consultation on a revised draft
17 August 2022 - The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised ...
Posted by Michael Wonder on 15 Aug 2022
One stop shop in Medicare shake-up
16 August 2022 - Doctors may be able to spend more time with patients, treat patients after-hours, and employ nurses, ...
Posted by Michael Wonder on 03 Aug 2022
PHARMAC tells MPs medicine buying agency undergoing 'substantial change'
3 August 2022 - PHARMAC has undergone “substantial change” in the past few years, even before a hard hitting review ...
Posted by Michael Wonder on 02 Aug 2022
PHARMAC scrutiny a win for transparency
2 August 2022 - “PHARMAC’s appearance before the Health Select Committee tomorrow morning is a triumph for transparency and the ...